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Summary
A new first-line antiretroviral therapy (ART) regimen containing dolutegravir is being rolled-out in 
low-income and middle-income countries (LMICs). Studies from predominantly high-income 
settings have found that dolutegravir-based regimens have superior efficacy, tolerability and 
durability compared with existing first-line regimens. However, several questions remain regarding 
the roll-out of dolutegravir in LMICs, where most people living with HIV are women of 
reproductive age, TB prevalence can be high, and access to viral load and HIV drug resistance 
testing is limited. Cohort studies suggest that dolutegravir is safe when initiated in pregnancy, but 
further data is required to determine the risk of adverse birth outcomes when dolutegravir is 
initiated pre-conception. Increasing access to viral load testing to monitor the effectiveness of 
dolutegravir remains crucial, but the optimal strategy to manage patients with viraemia is unclear. 
Furthermore, evidence demonstrating the effectiveness of dolutegravir when co-administered with 
tuberculosis treatment is scarce, particularly in programmatic settings in LMICs. Lastly, it is not 
known whether nucleoside reverse-transcriptase inhibitor resistance will affect the long-term 
efficacy of dolutegravir-based regimens in first-line, and potentially second-line ART. Clinical 
trials, cohorts and surveillance of HIV drug resistance will be required to answer these questions 
and to maximise the benefits of this new regimen.
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Introduction
In September 2017 a breakthrough pricing agreement was reached to provide generic 
dolutegravir for HIV treatment in low- and middle-income countries (LMICs).1 Combined 
with tenofovir disoproxil fumarate and lamivudine, this single pill, fixed-dose combination 
will cost approximately USD 75 per person per year,1 and is likely to be cost effective when 
compared to current non-nucleoside reverse transcriptase inhibitor (NNRTI) first-line 
regimens.2 Dolutegravir is an integrase strand transfer inhibitor (INSTI) with better 
tolerability, efficacy and durability than efavirenz.3 The World Health Organization (WHO) 
supports transitioning to dolutegravir-based first-line regimens, particularly in regions where 
pre-treatment drug resistance to NNRTIs reaches 10%, such as Southern and Eastern Africa.
4,5 Brazil and Botswana have already introduced dolutegravir into their public health sectors, 
with countries including Malawi, Nigeria, Tanzania and South Africa planning to launch the 
fixed-dose combination in 2018.6 While this could be a major improvement for HIV care in 
LMICs, specific key questions remain unanswered. Here, we outline uncertainties regarding 
safety in pregnancy, management of viraemia, tuberculosis (TB) drug interactions, immune 
reconstitution inflammatory syndrome (IRIS) and HIV drug resistance (HIVDR) which 
should be addressed during the roll-out of dolutegravir-based first-line ART in LMICs 
(Table 1).
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Is dolutegravir safe in pregnancy and during breastfeeding?
Dolutegravir has a favourable safety profile amongst older children, adolescents and adults, 
but a key concern has been the lack of evidence to support use in pregnancy and 
breastfeeding. Data from small cohorts of pregnant women who conceived while receiving 
dolutegravir in Europe and North America showed no evidence of increased birth defects.7,8 
In Botswana, 1729 pregnant women who were initiated on dolutegravir-based ART (of 
whom 280 were initiated in the first trimester) had no increase in adverse foetal outcomes 
when compared to 4593 pregnant women who were initiated on efavirenz-based regimens.9 
However, more recent data from Botswana suggests a possible increased risk of neural tube 
defects in infants born to women who where initiated on dolutegravir prior to conception.
10,11 In this preliminary analysis, 0.94% (4/426) of women receiving dolutegravir gave birth 
to an infant with a neural tube defect, compared with 0.13% (14/11 173) of women receiving 
non-dolutegravir-based regimens. Full results are expected in 2019, and pending further 
data, WHO recommend that women of childbearing age receive alternative ART regimens 
with better evidence to support safe use in pregnancy.10 With regard to efficacy, 
pharmacokinetic data from 29 pregnant women taking dolutegravir 50mg once daily found 
slightly lower maternal dolutegravir levels during the second and third trimesters, but this 
did not seem to impact greatly on viral outcomes or mother-to-child transmission.12 
Evidence from randomised clinical trials will be necessary to compare maternal and infant 
outcomes including safety, pharmacokinetics and virological efficacy between dolutegravir 
and other regimens.13 Two large trials have recently begun, but are only enrolling ART naïve 
pregnant women in the second and third trimesters.14,15 Therefore, surveillance of maternal 
and infant outcomes, particularly amongst women who conceive while receiving 
dolutegravir, will be important to confirm safety in pregnancy and whether dolutegravir can 
be recommended for use in women of child-bearing age..
Will the introduction of dolutegravir simplify the management of patients 
with viraemia?
The transition from efavirenz to a more efficacious dolutegravir-based first-line is hoped to 
increase levels of viral suppression in LMICs. However, ART stock outs, poor retention in 
care, funding constraints and increasing patient loads that pressurize healthcare systems may 
blunt the effectiveness of this new regimen. Expanding viral load coverage will therefore 
remain critical to monitor effectiveness of dolutegravir-based ART and to identify patients 
with viraemia who require intervention. However, the optimal strategy for viral load 
monitoring, particularly after detection of viraemia, will need to be reassessed, as some 
previous assumptions regarding management of treatment failure in adults will no longer be 
applicable.16 In high-income settings, the emergence of HIV drug resistance (HIVDR) 
mutations against dolutegravir has been rare.17,18 This contrasts sharply with current 
NNRTI-based first-line ART, where up to 89% of patients with first viraemia can have 
associated HIVDR mutations.19,20 In LMICs, where HIVDR testing is not widely available, 
WHO recommends switching to second-line ART if viraemia persists for more than three 
months, despite adequate adherence. While effective in clinical trials,21 these guidelines are 
often poorly implemented in public sector programmes, leading to ongoing viraemia, 
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morbidity and emergence and transmission of drug-resistant HIV.4,22,23 The roll-out of first-
line dolutegravir may allow simplification of these guidelines, as viraemia is likely to be 
caused by poor adherence in the absence of HIVDR, meaning switching from dolutegravir 
first-line to a second-line regimen should be greatly reduced. Instead, management of 
viraemia should shift from treating HIVDR to focus more intensely on improving adherence.
Does the dolutegravir roll-out provide an opportunity to re-evaluate 
adherence interventions?
Various adherence interventions have been evaluated in LMICs, but evidence demonstrating 
an effect on virological suppression is weak.24 Adherence relies on a complex mix of 
medical, behavioural, social and structural factors,25 which can be difficult to influence. 
Moreover, accurately measuring adherence is challenging.26 While a suppressed viral load 
demonstrates good adherence to current first-line regimens, a high viral load could be caused 
by HIVDR, rather than contemporaneous poor adherence. For non-adherent patients on 
dolutegravir, the shorter half-life27 when compared to efavirenz may result in faster viral 
rebound, while improved adherence should be reflected in a rapid return to viral 
suppression. Therefore, as dolutegravir use and viral load testing coverage increase, 
monitoring adherence, and response to adherence interventions, should become easier. This 
presents an important opportunity to develop and implement evidence-based adherence 
interventions to achieve early viral resuppression.28 Point-of-care viral load testing may be 
particularly useful here to rapidly identify adherence problems, monitor the impact of 
counselling, and efficiently triage patients into differentiated care services.29 Novel point-of-
care adherence assays (e.g. measuring urine tenofovir levels) are being developed, and their 
potential as additional or alternative monitoring strategies should be evaluated as part of the 
dolutegravir roll-out.30
How should dolutegravir be used in the context of TB treatment and 
prevention?
Uncertainty remains regarding optimal dosing of dolutegravir when co-administered with 
rifamycins, key drugs in treating the large numbers of people co-infected with HIV and TB 
in LMICs. Rifampicin induces the liver enzymes uridine glucuronosyltransferase 1A1 and 
cytochrome P450 3A4, which increase dolutegravir metabolism and decrease drug levels.31 
Interim data from the INSPIRING trial suggest that doubling the dolutegravir dose to 50 mg 
twice daily when co-administered with rifampicin could be effective, safe and tolerable for 
patients co-infected with HIV and TB, although full 48 week outcomes are forthcoming.32 
Adjusting the dolutegravir dose may be challenging to implement in public sector 
programmes and would negate the benefits of a once daily regimen, meaning further work is 
needed to assess the clinical impact of rifampicin co-administered with once daily 
dolutegravir.31 Some countries are therefore opting to continue efavirenz-based first-line 
ART in patients receiving TB treatment.33 With regard to treatment of latent TB infection, 
results from the BRIEF-TB trial mean one month of daily isoniazid and rifapentine is being 
considered as an effective, safer and shorter alternative to isoniazid monotherapy.34 
However, issues around cost and appropriate co-formulations are unresolved, and a phase I 
Dorward et al. Page 4
Lancet HIV. Author manuscript; available in PMC 2019 July 01.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
drug interaction study of dolutegravir and high dose, weekly isoniazid and rifapentine was 
stopped early due to serious toxicities.35 The precise underlying mechanisms remain 
unclear, and whether this interaction persists at the lower, daily doses used in BRIEF-TB 
requires urgent assessment. In the interim, daily isoniazid preventative therapy is likely to 
remain the preferred option in countries that roll out dolutegravir, as other short course 
regimens contain rifampicin and would require dolutegravir dose adjustments.
Will dolutegravir be associated with increased risk of IRIS in LMICs?
Evidence from European cohort studies has suggested a possible increased risk of IRIS, 
particularly TB related, amongst patients initiated on INSTI-based regimens, compared to 
NNRTI or protease inhibitor (PI)-based regimens.36–38 These findings were not replicated in 
a recent sub-analysis from REALITY, a multicentre, randomised, factorial trial of 1805 
participants in Eastern and Southern Africa. This study enrolled ART naïve children and 
adults with CD4 counts less than 100 cells per μL, and demonstrated that 12 weeks of 
raltegravir intensification alongside standard ART initiation did not impact incidence or 
mortality of IRIS.39 Data regarding dolutegravir-based ART is less conclusive. A meta-
analysis of randomised controlled trials found no association between dolutegravir and IRIS 
when compared to NNRTI and PI-based regimens. However, these studies had only 13 cases 
of IRIS between them and may not be generalisable to LMICs as they excluded patients with 
CDC grade C disease.40 Data from the Brazilian rollout reported only one case of IRIS 
amongst the first 26,070 ART naïve patients initiated on dolutegravir.41 Whilst these 
emerging findings are reassuring, further data from randomised trials such as the ADVANCE 
study,42 as well as cohort studies embedded in public sector programmes, will be important 
to establish the frequency of IRIS and its impact on mortality amongst patients receiving 
dolutegravir in LMICs.43
What impact will NRTI mutations have on dolutegravir-based regimens in 
LMICs, and what role will there be for HIVDR testing?
Recent evidence of dolutegravir resistance developing after use in monotherapy44 means the 
long-term implications of combining dolutegravir with a significantly compromised NRTI 
backbone must be considered. This could occur more frequently in LMICs due to the 
paucity of HIVDR testing and incomplete viral load coverage. Firstly, adults with 
pretreatment drug resistance (particularly those with previous ART exposure) may have 
undetected NRTI mutations associated with reduced susceptibility to tenofovir and 
lamivudine.23 Second, in Southern Africa, long delays in management of viraemia have 
been documented, which could allow emergence of NRTI resistance while on dolutegravir.
22,45 Third, several studies have reported high levels of K65R and M184V mutations 
amongst adults failing current first-line regimens in LMICs.46 Therefore, if people are 
switched from tenofovir, emtricitabine and efavirenz, to tenofovir, lamivudine and 
dolutegravir without confirmation of viral suppression, there may be a higher risk of 
acquired dolutegravir HIVDR. Understanding the risks and benefits of such a strategy is a 
priority research question, as several ART programmes are not using viral load testing in the 
transition to dolutegravir-based first line ART.33 While the advantages of dolutegravir might 
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justify this approach, programs should be supported in accelerating viral load roll out and 
implementing HIVDR surveillance systems to guide policy decisions.
Recent results from the DAWNING trial provide some evidence regarding the impact of 
NRTI resistance on dolutegravir-based regimens.47 In DAWNING, patients failing first-line 
NNRTI-based ART were randomized to receive a dolutegravir- or protease inhibitor (PI)-
based second-line regimen. In both the dolutegravir and PI arms, those with only one 
predicted active NRTI did better than those with two,47 as has been seen in other studies of 
PI-based second-line regimens.48–50 However, in all these studies, there were few patients 
who failed a tenofovir first-line regimen and then received tenofovir in their second-line 
regimen. Furthermore, confounding due to the difficulties of accurately measuring and 
controlling for poor adherence may explain some of these findings. In short, there is little 
high quality evidence demonstrating the long-term efficacy of dolutegravir alongside a 
compromised NRTI backbone.51,52 Therefore, as dolutegravir is rolled out, HIVDR 
surveillance will be crucial to determine the incidence of both NRTI and dolutegravir 
HIVDR mutations, their impact on clinical outcomes and the need for, timing and cost-
effectiveness of HIVDR testing in public sector programmes. This will require the 
development of INSTI HIVDR testing capacity in LMICs, and could be aided by new 
targeted HIVDR testing platforms or point-of-care resistance assays.53 If found to be 
affordable and effective, these assays could be incorporated into algorithms to screen for and 
manage treatment failure on first-line dolutegravir, and guide selection of subsequent 
second-line regimens if necessary.
Should dolutegravir replace current first and second-line ART?
Several LMICs have prioritized ART naïve patients for initiation of dolutegravir based first-
line ART, followed by transition of patients from NNRTI-based regimens to dolutegravir. 
While some patients may request to remain on effective NNRTI regimens, programmatic 
factors such as simplification of supply chain, ART tenders and training mean that 
transitioning the majority of stable patients to dolutegravir-based first-line should be 
encouraged, as long as concerns regarding safety in pregnancy have been addressed. There is 
also interest in dolutegravir to replace current second-line regimens, with the DAWNING 
trial demonstrating that a dolutegravir-based regimen was superior to a PI-based regimen 
amongst patients failing first-line NNRTI-based ART.47 All participants in this study had at 
least one predicted fully active NRTI, with HIVDR testing used to select the second-line 
NRTI backbone, an approach which is not currently feasible in most LMICs. Despite this, 
results from DAWNING, coupled with significant cost savings,54 have led some countries to 
consider dolutegravir as a replacement for current first- and second-line therapies.55 Given 
the evidence currently available, in the absence of HIVDR testing it would seem prudent to 
ensure that patients with treatment failure on current tenofovir containing first-line ART are 
switched to zidovudine in a dolutegravir-based second-line regimen. In settings where viral 
load testing is unavailable, this would include patients with WHO clinical or immunological 
failure. Therefore, in the majority of cases, the tenofovir, lamivudine and dolutegravir fixed-
dose combination could not be used for second-line ART.
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Conclusion
In summary, the impending roll-out of dolutegravir as first-line ART has potential to be 
another important step in the evolution of HIV treatment programmes in LMICs. The 
superior durability of this INSTI should simplify treatment pathways, and coupled with 
increasing viral load coverage, presents an opportunity to focus on improving ART 
adherence to increase levels of viral suppression. Despite these benefits, a number of gaps in 
the evidence base must be addressed by researchers as part of the dolutegravir roll-out, in 
particular regarding safety in pregnancy. Using data from dolutegravir cohorts, clinical trials 
and HIVDR surveillance will allow health systems to maximize the potential benefits of this 
exciting new regimen.
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Table 1
Questions that need to be addressed in the roll-out of dolutegravir in low- and middle-income countries
Safety
• Is the use of dolutegravir in pregnancy associated with adverse birth outcomes?
• What is the frequency and impact of immune reconstitution inflammatory syndrome amongst severely immunocompromised 
patients who are initiated on dolutegravir in LMICs?
Monitoring effectiveness
• What is the optimal strategy for viral load and HIVDR testing to manage adults with viraemia on dolutegravir-based regimens?
• For patients with viraemia on dolutegravir, how can adherence support interventions be integrated with viral load monitoring to 
maximize virological re-suppression?
Drug interactions
• Will co-administration of dolutegravir and rifampicin in patients with HIV/TB impact on HIV treatment outcomes?
HIV drug resistance
• At what rate will dolutegravir HIV drug resistance mutations emerge in LMIC public sector programmes, and in which clinical 
scenarios?
• How will pretreatment or acquired NRTI drug resistance mutations impact on the efficacy of dolutegravir-based first or second-
line regimens?
Implications for second-line ART
• If resistance to dolutegravir-based first-line occurs in LMICs, what will be the best second-line regimen and what is the optimal 
timing for regimen switch?
• For patients failing current NNRTI-based first-line ART, should dolutegravir be used in a second-line regimen?
Cost-effectiveness
• Will replacing current first- and/or second-line regimens with dolutegravir-based regimens prove cost-effective?
• How will the roll-out of dolutegravir impact the cost-effectiveness of viral load monitoring and HIV drug resistance testing?
ART – antiretroviral therapy, HIVDR – HIV drug resistance, LMIC – low- and middle-income country, NNRTI – non-nucleoside reverse 
transcriptase inhibitor, NRTI – nucleoside reverse transcriptase inhibitor
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